Chemomab's 2025 Critical Trial Advances New Drug Approval
"2025 was a critical year for Chemomab and our nebokitug program," said Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab. "Our Phase 2 SPRING trial data, viewed by many experts as the strongest to date in PSC, set the stage for our positive FDA End-of-Phase 2 meeting, which resulted in alignment on a clear pathway to potential regulatory approval based on a single Phase 3 trial. This pivotal trial will assess a primary composite endpoint comprised of well-characterized clinical events that are associated with disease progression in PSC. We believe that using a clinical event-driven endpoint helps de-risk the Phase 3 program, as key publications have linked the PSC-related biomarker improvements observed in nebokitug-treated patients in the SPRING trial with reductions in clinical events. Our discussions with potential strategic partners continue to advance as we progress activities required for the timely initiation of the Phase 3 trial in PSC. In parallel, we are evaluating additional therapeutic indications where nebokitug has generated robust preclinical efficacy signals, providing a strong mechanistic and translational rationale for future clinical development."
Trade with 70% Backtested Accuracy
Analyst Views on CMMB
About CMMB
About the author
Market Update: Tilray Drives After-Hours Gains as Biotech Stocks Soar
Tilray Brands Surge: Tilray Brands, Inc. saw an 11.36% increase in after-hours trading, reaching $13.53, following a one-for-ten reverse stock split and positive investor sentiment regarding its restructuring and beverage portfolio.
Valneva's Positive Trial Results: Valneva SE's stock rose by 7.22% after hours to $9.31, buoyed by favorable final data from its Phase 2 chikungunya vaccine trial, which supports future Phase 3 development plans.
Chemomab and Genenta Recovery: Chemomab Therapeutics Ltd. gained 7.66% after hours to $2.39, while Genenta Science S.p.A. climbed 12.06% to $1.58, both recovering from earlier declines and reacting to recent clinical trial updates.
Kazia and Traws Pharma Movements: Kazia Therapeutics Limited increased by 10.93% after hours to $11.57, following a presentation on its cancer treatment, while Traws Pharma, despite no new developments, edged up 8.81% to $2.54, driven by low-float trading momentum.
Top Strong Buy Stocks for October 23: MQ, GES, and Others
Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including Marqeta, Guess?, The Travelers Companies, Chemomab Therapeutics, and Par Pacific Holdings, with significant increases in their earnings estimates over the past 60 days.
Quantum Computing Revolution: Quantum computing is rapidly advancing and is seen as the next major technological revolution, with major companies like Microsoft, Google, and Amazon integrating it into their infrastructure.
Investment Opportunities: Senior Stock Strategist Kevin Cook has identified seven stocks that are expected to lead in the quantum computing sector, suggesting a potential investment opportunity for those looking to capitalize on this emerging technology.
Free Stock Analysis Reports: The article offers free stock analysis reports for the highlighted companies, providing additional insights for investors interested in these stocks.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
ESPR Seeks Diversification Through Rare Liver Disease Candidate, Shares Rise
New Development Candidate: Esperion Therapeutics has nominated ESP-2001, an allosteric ATP citrate lyase inhibitor, for preclinical development aimed at treating primary sclerosing cholangitis (PSC), a rare autoimmune liver disease with no current approved treatments.
Market Potential and Financial Performance: If successful, ESP-2001 could tap into a market opportunity exceeding $1 billion annually, while Esperion's existing products, Nexletol and Nexlizet, have seen a 42% increase in U.S. sales, contributing to the company's growth amidst a rising stock price.
CDTX Shares Rise Following FDA's Breakthrough Therapy Designation for CD388 in Influenza
FDA Breakthrough Therapy Designation: Cidara Therapeutics received FDA Breakthrough Therapy designation for its candidate CD388, aimed at preventing seasonal influenza, leading to a 12.4% increase in the company's shares.
CD388's Mechanism and Efficacy: CD388 is a long-acting small molecule inhibitor that offers broad protection against seasonal and pandemic flu strains, requiring only a single injection for an entire flu season, independent of the body's immune response.
Oppenheimer Reiterates Outperform Rating for Chemomab Therapeutics and Increases Price Target to $25
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
Market Update: Tilray Drives After-Hours Gains as Biotech Stocks Soar
Tilray Brands Surge: Tilray Brands, Inc. saw an 11.36% increase in after-hours trading, reaching $13.53, following a one-for-ten reverse stock split and positive investor sentiment regarding its restructuring and beverage portfolio.
Valneva's Positive Trial Results: Valneva SE's stock rose by 7.22% after hours to $9.31, buoyed by favorable final data from its Phase 2 chikungunya vaccine trial, which supports future Phase 3 development plans.
Chemomab and Genenta Recovery: Chemomab Therapeutics Ltd. gained 7.66% after hours to $2.39, while Genenta Science S.p.A. climbed 12.06% to $1.58, both recovering from earlier declines and reacting to recent clinical trial updates.
Kazia and Traws Pharma Movements: Kazia Therapeutics Limited increased by 10.93% after hours to $11.57, following a presentation on its cancer treatment, while Traws Pharma, despite no new developments, edged up 8.81% to $2.54, driven by low-float trading momentum.
Top Strong Buy Stocks for October 23: MQ, GES, and Others
Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including Marqeta, Guess?, The Travelers Companies, Chemomab Therapeutics, and Par Pacific Holdings, with significant increases in their earnings estimates over the past 60 days.
Quantum Computing Revolution: Quantum computing is rapidly advancing and is seen as the next major technological revolution, with major companies like Microsoft, Google, and Amazon integrating it into their infrastructure.
Investment Opportunities: Senior Stock Strategist Kevin Cook has identified seven stocks that are expected to lead in the quantum computing sector, suggesting a potential investment opportunity for those looking to capitalize on this emerging technology.
Free Stock Analysis Reports: The article offers free stock analysis reports for the highlighted companies, providing additional insights for investors interested in these stocks.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
ESPR Seeks Diversification Through Rare Liver Disease Candidate, Shares Rise
New Development Candidate: Esperion Therapeutics has nominated ESP-2001, an allosteric ATP citrate lyase inhibitor, for preclinical development aimed at treating primary sclerosing cholangitis (PSC), a rare autoimmune liver disease with no current approved treatments.
Market Potential and Financial Performance: If successful, ESP-2001 could tap into a market opportunity exceeding $1 billion annually, while Esperion's existing products, Nexletol and Nexlizet, have seen a 42% increase in U.S. sales, contributing to the company's growth amidst a rising stock price.
CDTX Shares Rise Following FDA's Breakthrough Therapy Designation for CD388 in Influenza
FDA Breakthrough Therapy Designation: Cidara Therapeutics received FDA Breakthrough Therapy designation for its candidate CD388, aimed at preventing seasonal influenza, leading to a 12.4% increase in the company's shares.
CD388's Mechanism and Efficacy: CD388 is a long-acting small molecule inhibitor that offers broad protection against seasonal and pandemic flu strains, requiring only a single injection for an entire flu season, independent of the body's immune response.
Oppenheimer Reiterates Outperform Rating for Chemomab Therapeutics and Increases Price Target to $25
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
